Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
S B KayeAndres Poveda

Abstract

OVA-301 is a large randomized trial that showed superiority of trabectedin plus pegylated liposomal doxorubicin (PLD; CentoCor Ortho Biotech Products L.P., Raritan, NJ, USA). over single-agent PLD in 672 patients with relapsed ovarian cancer, particularly in the partially platinum-sensitive subgroup [platinum-free interval (PFI) of 6-12 months]. This superiority has been suggested to be due to the differential impact of subsequent (platinum) therapy. a detailed analysis of subsequent therapies and survival outcomes in the overall population and in the subsets according to platinum sensitivity was therefore conducted. similar proportions of patients received subsequent therapy in each arm (76% versus 77%), including further platinum-based regimens (49% versus 55%). Patients in the trabectedin/PLD arm received subsequent chemotherapy at a later time (median delay 2.5 months versus PLD arm). Overall survival from subsequent platinum was significantly prolonged in the partially platinum-sensitive disease subset (hazard ratio = 0.63; P = 0.0357). the superiority of trabectedin/PLD over single-agent PLD in OVA-301 cannot be explained by differences in the extent or nature of subsequent therapies administered to these patients. On the...Continue Reading

References

Jun 18, 2002·The Oncologist·Maurizio D'IncalciGlynn T Faircloth
Sep 18, 2003·Gynecologic Oncology·David Spriggs
Oct 8, 2003·Gynecologic Oncology·Mario M LeitaoDavid R Spriggs
Mar 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cristiana SessaNicoletta Colombo
Apr 13, 2005·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·H T SeeJ J Kavanagh
May 24, 2006·Seminars in Oncology·Jacobus Pfisterer, Jonathan A Ledermann
Jun 30, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D LorussoG Scambia
Jan 26, 2008·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·T T NguyenD G Mutch
Jun 27, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J M Del CampoUNKNOWN Yondelis Ovarian Cancer Group
Sep 12, 2009·Expert Opinion on Pharmacotherapy·Kristen N Ganjoo, S R Patel
Jan 9, 2010·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Bradley J Monk, Robert L Coleman
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bradley J MonkAndrés M Poveda

❮ Previous
Next ❯

Citations

Nov 18, 2010·Archives of Gynecology and Obstetrics·Ansgar Brüning, Ioannis Mylonas
Jul 31, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Fausto PetrelliSandro Barni
Nov 10, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C Sessa, M D'Incalci
Jul 8, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J SehouliA González-Martín
Oct 4, 2012·Future Oncology·Klaus H BaumannAndreas du Bois
Nov 8, 2015·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·G CollocaI Governato
Apr 17, 2012·Current Opinion in Pharmacology·John A Hartley, Daniel Hochhauser
Mar 7, 2012·Cancer·Matthias PreusserWalter Berger
Dec 4, 2013·Cancer Treatment Reviews·Andrés PovedaNicoletta Colombo
Jan 2, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M E L van der BurgH C van Doorn
Oct 25, 2016·Cancer Treatment Reviews·Bradley J MonkMaurizio D'Incalci
Feb 1, 2017·Expert Opinion on Pharmacotherapy·Eleonora Teplinsky, Thomas J Herzog
Oct 25, 2014·Therapeutic Advances in Medical Oncology·Daniela LuveroJonathan A Ledermann
Oct 13, 2017·Future Oncology·Isabelle Ray-Coquard
May 6, 2011·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Nicoletta Colombo
Jun 3, 2017·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Gabriella FerrandinaGiovanni Scambia
Feb 1, 2011·Journal of Gynecologic Oncology·Dong Hoon SuhSoon-Beom Kang
Jul 10, 2013·The Cochrane Database of Systematic Reviews·Theresa A LawrieJo Morrison
Sep 20, 2018·Current Drug Delivery·Tapan Kumar Giri
Dec 30, 2017·Oncology Letters·Zhen HuangBeihua Kong
Sep 21, 2018·American Society of Clinical Oncology Educational Book·Franziska Maria IppenPriscilla Kaliopi Brastianos
Jan 15, 2019·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Elisa TripodiDomenica Lorusso
Dec 14, 2018·Molecular and Clinical Oncology·Alessandro VillanucciEnrico Mini
Jan 17, 2019·Neuro-oncology·Priscilla K BrastianosUNKNOWN International Consortium on Meningiomas
Nov 11, 2020·BMJ : British Medical Journal·Lindsay Kuroki, Saketh R Guntupalli
Aug 17, 2012·Molecular Cancer Research : MCR·Natasha Musrap, Eleftherios P Diamandis
Mar 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J SehouliA González-Martín
Jul 6, 2019·Case Reports in Oncology·Eva María Guerra AlíaBelén Pérez Miez

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.